%0 Journal Article
%T 前列腺导管内癌患者临床病理特征及预后研究
%A 陈欣怡　谷勤勤　亓永云　韩博
%J -
%D 2020
%R 10.13362/j.jpmed.202001007
%X 摘要 目的　比较前列腺导管内癌（IDC-P）组和非IDC-P组患者临床病理特征及预后。 方法　对山东大学齐鲁医院确诊为前列腺癌的282例穿刺标本进行回顾性分析，通过免疫组化方法确定IDC-P的发生情况，记录IDC-P组和非IDC-P组患者的年龄、术前前列腺特异抗原(PSA）水平、术前骨转移情况、临床T分期、Gleason分级分组，并通过电话随访记录两组患者的总生存和疾病特异生存情况，最后进行比较。 结果　检测出IDC-P患者21例，IDC-P在前列腺癌中的构成比为7.45%（21/282）。IDC-P组患者术前PSA水平升高、发生骨转移患者构成比明显高于非IDC-P组患者(χ2=7.019、5.392，P＜0.05)。Kaplan-Meier生存分析显示，IDC-P组患者的总生存率及疾病特异生存率均显著低于非IDC-P组患者（χ2=9.964、10.294，P＜0.05）。Cox模型多因素分析显示，IDC-P是前列腺癌患者总生存及疾病特异生存的独立危险因素(Wald χ2=4.580、4.498，P＜0.05)。 结论　IDC-P是影响前列腺癌患者预后的独立危险因素。<br>Abstract：Objective　To compare clinicopathological features and prognosis between patients with intraductal carcinoma of the prostate (IDC-P) and non-IDC-P patients with prostate cancer. Methods　A retrospective analysis was performed on biopsy specimens from 282 patients who were confirmed with prostate cancer in Qilu Hospital of Shandong University. The patients with IDC-P were identified by immunohistochemistry. The IDC-P group and the non-IDC-P group were compared in terms of age, preoperative prostate-specific antigen (PSA) level, preoperative bone metastases, clinical T stage, and Gleason grade, as well as their overall survival and disease-specific survival, which were recorded by telephone follow-up. Results　 Twenty-one cases of IDC-P were detected, accounting for 7.45% of all prostate cancer patients. The IDC-P group had significantly higher proportions of patients with an increased preoperative PSA level and those with bone metastases than the non-IDC-P group (χ2=7.019,5.392,P<0.05). Kaplan-Meier survival analysis showed that the overall survival rate and disease-specific survival rate were significantly lower in the IDC-P group than in the non-IDC-P group (χ2=9.964,10.294,P<0.05). Multivariate Cox analysis showed that IDC-P was an independent risk factor for overall survival and disease-specific survival (Wald χ2=4.580,4.498,P<0.05). ConclusionI　DC-P is an independent risk factor affecting the prognosis of patients with prostate cancer
%K 癌
%K 导管内
%K 前列腺肿瘤
%K 病理学
%K 预后
%K 存活率<br>Carcinoma
%K intraductal
%K Prostatic neoplasms
%K Pathology
%K Prognosis
%K Survival rate
%U http://jpmed.qdu.edu.cn/CN/10.13362/j.jpmed.202001007